PharmaCorp Rx Management
Management criteria checks 1/4
PharmaCorp Rx's CEO is Grady Brown, appointed in Jun 2024, has a tenure of 2.08 years. directly owns 0.52% of the company’s shares, worth CA$453.87K. The average tenure of the management team and the board of directors is 2.1 years and 2.1 years respectively.
Key information
Grady Brown
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 2.1yrs |
| CEO ownership | 0.5% |
| Management average tenure | 2.1yrs |
| Board average tenure | 2.1yrs |
Recent management updates
Recent updates
CEO
Grady Brown
Mr. Grady Brown is CEO & Director of PharmaCorp Rx Inc. from June 6, 2024. He is a former co-CEO of PharmaChoice and now current CEO of PharmaChoice. Mr. Brown embarked on his professional journey in the p...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairperson | 4.8yrs | CA$109.80k | 5.62% CA$ 4.9m | |
| CEO & Director | 2.1yrs | CA$97.99k | 0.52% CA$ 453.9k | |
| President & COO | 2.1yrs | CA$232.65k | 0.35% CA$ 306.5k | |
| Chief Financial Officer | 2.1yrs | CA$51.30k | 0.022% CA$ 18.7k | |
| Strategic Advisor to CEO & Director | less than a year | CA$53.30k | 0.36% CA$ 312.5k | |
| Corporate Secretary | no data | CA$36.05k | 1.21% CA$ 1.0m |
Experienced Management: PCRX's management team is considered experienced (2.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairperson | 4.8yrs | CA$109.80k | 5.62% CA$ 4.9m | |
| CEO & Director | 2.1yrs | CA$97.99k | 0.52% CA$ 453.9k | |
| Strategic Advisor to CEO & Director | 2.1yrs | CA$53.30k | 0.36% CA$ 312.5k | |
| Independent Director | 4.8yrs | CA$16.45k | 0.79% CA$ 687.5k | |
| Independent Director | 2.1yrs | CA$5.03k | 0.64% CA$ 554.9k | |
| Independent Director | 2.1yrs | CA$5.03k | 0.42% CA$ 369.1k | |
| Independent Director | 2.1yrs | CA$4.78k | 0.51% CA$ 440.5k |
Experienced Board: PCRX's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/15 14:25 |
| End of Day Share Price | 2026/07/15 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
PharmaCorp Rx Inc. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nick Corcoran | Acumen Capital Finance Partners Limited |
| Tania Armstrong-Whitworth | Canaccord Genuity |
| Fred Gatali | Raymond James Ltd. |